This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Aprea Therapeutics’s 8K filing here.
About Aprea Therapeutics
Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.
Featured Stories
- Five stocks we like better than Aprea Therapeutics
- What is Put Option Volume?
- AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders
- Why Are Stock Sectors Important to Successful Investing?
- TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
- Comparing and Trading High PE Ratio Stocks
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
